Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA Japan registry entry
jRCT2080223253Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223253.